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Abstract
Respiratory Syncytial virus (RSV) is the leading cause of acute lower respiratory tract viral infection in young children and a
major cause of winter hospitalization. Bordetella pertussis is a common cause of bacterial lung disease, affecting a similar age
group. Although vaccines are available for B. pertussis infection, disease rates have recently increased in many countries. We
have therefore developed a novel live attenuated B. pertussis strain (BPZE1), which has recently undergone a successful
clinical phase I trial. In mice, BPZE1 provides protection against disease caused by respiratory viral challenge. Here, we
analyze the effect of BPZE1 on antiviral T cell responses induced by human monocyte-derived dendritic cells (MDDC). We
found that BPZE1 influences antiviral immune responses at several levels, enhancing MDDC maturation, IL-12p70
production, and shifting T cell cytokine profile towards a Th1/Th17 pattern. These data were supported by the intracellular
signaling analysis. RSV infection of MDDC caused MyD88-independent STAT1 phosphorylation, whereas BPZE1 activated
MyD88-dependent signaling pathways; co-infection caused both pathways to be activated. These findings suggest that
BPZE1 given during infancy might improve the course and outcome of viral lung disease in addition to providing specific
protection against B. pertussis infection.
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Introduction
Respiratory Syncytial virus (RSV), a single-stranded RNA virus
in the Paramyxoviridae family, is the leading cause of acute lower
respiratory tract infections in infants and the single major cause of
childhood hospitalization in the developed world [1]. Approxi-
mately 60% of all children are infected with RSV in the first year
of life, increasing to 90% by their second year of life [2]. Despite
the presence of serum antibody, RSV re-infects throughout life.
Globally, RSV is thought to cause almost 34 million cases per year
of acute lower respiratory tract infection in children under 5 years
of age, 10% of them being severe. Infantile bronchiolitis is
associated with recurrent wheezing in older children [3–5]. It is
thought that RSV bronchiolitis represents an overactive host
immune response to infection [6], and there is still no safe and
effective RSV vaccine for human use. Indeed, the human trials of
formaldehyde-inactivated RSV vaccine in 1966–1967 caused
disastrous worsening of disease and death in infants during
subsequent natural RSV infection [7,8].
A live attenuated B. pertussis vaccine strain, named BPZE1, has
been developed as a vaccine candidate against whooping cough
[9]. It has successfully completed a phase I safety trials (http://
www.child-innovac.org) [10]. BPZE1 induces strong Th1 respons-
es in mice, and long-lasting protective immunity against B. pertussis
after a single nasal administration. It has proven safe, even in
neonatal and immunodeficient animals [11,12]. Moreover, Li
et al. [13], recently, reported that nasal administration of BPZE1
provides effective protection against lethal challenge with highly
virulent mouse-adapted H3N2 and H1N1 (A/PR/8/34) influenza
A viruses by controlling influenza virus-mediated inflammation
[13].
Dendritic cells (DC) constantly monitor the lungs for pathogens
or foreign antigens and play a key role in the initiation of
inflammatory responses at the mucosal surface. Local DC become
activated during RSV infection [14,15]. They acquire viral
antigens, undergo maturation and migrate to the lung-draining
lymph nodes, where they present peptide epitopes to prime naive
T cells [15].
We have previously demonstrated that BPZE1 is able to mature
and activate human monocyte-derived DC (MDDC) and to
induce the release of pro-inflammatory and regulatory cytokines.
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In addition, BPZE1-primed MDDC drive a mixed Th1/Th17
polarization and induce functional T suppressor cells [16].
RSV and B. pertussis can naturally co-infect infants, but children
with co-infection appear to experience a milder disease [17].
Schnoeller and colleagues demonstrated that BPZE1 protects
against RSV disease in a respiratory viral challenge mouse model
via an IL-17-dependent mechanism [18]. We therefore tested the
capacity of live attenuated BPZE1 to rescue RSV-induced
immune responses in the pre-clinical human MDDC model and
explored the intracellular signaling pathways involved. We found
BPZE1 co-infected with RSV enhances maturation of MDDC and
drives the T cells polarization to a putative protective Th1/Th17
response.
Materials and Methods
Ethics Statement
This study was conducted according to the principles of the
Declaration of Helsinki [19]. Peripheral blood was collected from
healthy blood donors at the Centro Trasfusionale Policlinico
Umberto I, University La Sapienza blood bank (Rome, Italy,
courtesy of Dr. Girelli). The blood samples were handed over
anonymously. None of the authors were involved in collecting the
blood samples or had access to patient identifying information.
All blood donors provided written informed consent for the
collection of samples and subsequent analysis. Blood samples were
processed anonymously, the materials once used for the experi-
ments were then destroyed, genetic research or interventions that
include genome were not included in the research protocol. This
study was conducted within the project ChildINNOVAC, in
compliance with European Commission FP7 ethical rules, a
specific IRB for this research was not approached.
Preparation of RSV stocks
Plaque-purified human RSV (type A2 strain from the ATCC)
was grown in HEp-2 cells [20] with Dulbecco’s modified Eagle’s
medium (DMEM, Life Technologies Invitrogen, Paisley, UK),
containing heat inactivated 10% Foetal Bovine Serum (FBS;
Hyclone Laboratories, South Logan, UT). Mock-infected HEp-2
cells were similarly processed to generate the mock control stock
preparation. Viral titers were determined by plaque assay, as
described [20].
Bacterial strain and growth conditions
The BPZE1 strain is derived from B. pertussis Tohama I. It is
devoid of pertussis toxin enzymatic activity, lacks dermonecrotic
toxin and is deficient in tracheal cytotoxin release as previously
described [9]. BPZE1 was grown on charcoal agar plates
supplemented with 10% defibrinated sheep blood (Biotec,
Grosseto, Italy) for 48 h at 37uC. Bacteria were then collected
and suspended in 2 ml phosphate-buffered saline (PBS), and the
concentration was estimated by measuring the optical density
(OD) at 600 nm. The suspensions were adjusted to a final
concentration of 109 colony-forming units (CFU)/ml. The
bacterial concentration was then checked retrospectively by
CFU evaluation of the final bacterial suspension.
Purification and culture of MDDC
Human monocytes were purified from peripheral blood
lymphocytes were isolated by using Ficoll gradients (lympholyte-
H; Cedarlane, Burlington, Ontario). CD14 cells were purified by
positive sorting through anti-CD14 mAb-conjugated magnetic
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and
cultured in 75 cm2 flasks (Costar, Corning Life Sciences, Tewks-
bury, MA) in RPMI 1640 medium (Life Technologies Invitrogen),
supplemented with heat-inactivated 10% lipopolysaccharide-free
FBS, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids,
2 mM L-glutamine, 25 mM HEPES, 100 U/ml penicillin,
100 mg/ml streptomycin (all from EuroClone, Milan, Italy) and
0.05 mM 2-bmercaptoethanol (Sigma Chemicals; St. Louis, MO)
in the presence of human recombinant GM-CSF (25 ng/ml; R&D
Systems, Minneapolis, MN) and IL-4 (25 ng/ml; R&D Systems)
[21]. After 6 d, immature MDDC were washed and analyzed by
cytofluorimetry for the expression of the surface markers CD1a,
CD14, CD83 and CD38. MDDC were used in the experiments if
.80% CD1a and ,10% CD14 positive cells.
Infection of MDDC with RSV and/or BPZE1
MDDC (106 cell/ml) were incubated with RSV at multiplicity
of infection (MOI) of 1 and/or with BPZE1, at bacteria- to- cells
ratio of 100:1. After 2 h at 37uC cells were extensively washed in
the presence of polymyxin B at 5 mg/ml (Sigma Chemicals) to kill
extracellular bacteria and incubated in 1 ml of complete medium
at 37uC, 5% CO2 [16]. In all experiments mock control was added
to MDDC. At 24 h post infection, MDDC were harvested for
immunophenotypic analysis, and the supernatants were collected
for cytokine measurement by ELISA.
RSV RT-PCR
RNA was extracted from MDDC cultures following RSV or
mock infection, and the concentration and quality of the RNA
were determined by spectrophotometry. Reverse transcription was
carried out as previously described [20] using 1 mg of total RNA
for cDNA synthesis. qPCR specific for the RSV L gene was
performed using 900 nM forward primer (59-GAACTCAGTG-
TAGGTAGAATGTTTGCA-39), 300 nM reverse primer (59-
TTCAGCTATCATTTTCTCTGCCAAT-39), and 175 nM
probe (59-6-carboxyfluorescein-TTTGAACCTGTCTGAA-
CATTCCCGGTT-6-carboxytetramethylrhodamine-39). Copy
numbers were determined from standard curves of pCDNA3
containing a fragment of the RSV L-gene [20].
Apoptosis detection
Apoptosis of MDDC was detected by using the Annexin V-
FITC Apoptosis Detection Kit (eBioscience, San Diego, CA) [22].
Briefly, MDDC were treated with stimuli for either 24 or 48 h, as
indicated, harvested and double-stained with FITC-conjugated
annexin V and propidium iodide, according to the manufacturer’s
protocol. Cells were analyzed by flowcytometry in a FACScan (BD
Biosciences, San Jose, CA) using CellQuest software. Data are
expressed as % of positive cells.
Immunophenotypic analysis
Cells were washed, suspended in PBS containing 3% FBS and
0.09% NaN3, and incubated with a panel of fluorochrome-
conjugated mAbs (obtained from BD Biosciences) specific for
MDDC differentiation/maturation (anti- CD80, CD83 and
CD38) [16]. Isotype-matched Abs were used as negative controls.
Cells were analyzed with a FACScan (BD Biosciences). Fluores-
cence data were reported as percentages of positive cells when the
treatment induced the expression of the marker in cells that were
negative (CD83). Median fluorescence intensity (MedFI) was used
when the treatment increased the expression of the marker in cells
that were already positive (CD80 and CD38).
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Determination of cytokine levels by ELISA
To measure cytokine production by infected MDDC, superna-
tants were collected, and IL-10, IL-12p70 and IL-23 production
were assessed by ELISA [16]. The lower detection limits were: IL-
10:3.9 pg/ml, IL-12p70:5.0 pg/ml, IL-23:20.0 pg/ml. Cytokines
in the supernatants from polarized T cells were assayed by ELISA
specific for IFNc, IL-5 and IL-17. The lower detection limits were:
IFNc: 8.0 pg/ml, IL-5:3.0 pg/ml, IL-17:15.0 pg/ml. OD ob-
tained was measured with a 3550-ultraviolet Microplate Reader
(BioRad, Philadelphia, PA) at 450 nm. All ELISA kits were from
Quantikine, R&D Systems, except for IL-23 (Bender Med System,
Burlingame, CA).
Isolation of T lymphocytes and MDDC-T cell allogeneic
MLR
CD3 T cells were purified from PBMC by negative sorting with
magnetic beads (Pan T-cell Kit, Miltenyi Biotec). Purity of cell
preparations was higher than 95%, as assessed by cytofluorimetric
staining. RSV-, BPZE1- or double- infected MDDC were cultured
in MLR with fresh allogeneic T cells (3 x 105) at different MDDC/
T cell ratios in 48-well cell culture plates for 6 d. Cell proliferation
was measured by Bromodeoxyuridine (BrdU) (BD Biosciences)
incorporation [16]. Briefly, BrdU was added to the MDDC and T
cells at 3 mg/ml final concentration on d 3 of culture. Cells,
collected on d 6, were fixed in 0.5% paraformaldehyde,
permeabilized and stained for intracellular BrdU by direct
immunofluorescence with a FITC-conjugated anti-BrdU mAb
with DNase (BD Biosciences). Cells were examined by flow
cytometry, and T cell proliferation was evaluated as percentage of
BrdU-positive cells.
Polarization of T lymphocytes
To evaluate T-lymphocyte polarization, experiments were
performed using fresh allogeneic CD3 T cells purified by negative
sorting with the PanT isolation kit (Miltenyi Biotec). Purity of cell
preparations was higher than 95%, as assessed by cytofluorimetric
staining. MDDC were treated with RSV and/or BPZE1 for 48 h,
washed extensively, and then co-cultured (0.56105) with CD3 T
cells (0.56106) in 24-well plates (Costar, Corning Life Sciences).
On d 6, rIL-2 at 50 U/ml (PeproTech, Rocky Hill, NJ) was added
to the cultures. On d 12, supernatants were harvested for cytokine
measurement by ELISA [16].
Determination of protein kinase phosphorylation by
Western blot analysis
MDDC were mock infected or challenged with BPZE1, RSV,
BPZE1/RSV for 20 min or 2 h and then lysed using RIPA buffer
as previously described [23]. For the 24 h time point, the cells
were infected for 2 h, then extensively washed in the presence of
polymyxin B (5 mg/ml), incubated in complete medium at 37uC,
5% CO2 for 24 h and then lysed using RIPA buffer. Immuno-
reactive proteins were detected by incubating blots with anti-
phosphorylated proteins overnight at 4uC. Rabbit polyclonal IgG
anti-p-p44/42 mitogen-activated protein kinases (MAPK)
(Thr202/Tyr204, ERK1/2), anti-p-p38 MAPK (Thr180/
Tyr182), anti-p-I kappa B alpha (IkBa) (Ser32), anti-p-stat1
(Tyr701) were from Cell Signaling Technology, Inc. (Danvers,
MA). Rabbit anti-b actin was from Hyclone Laboratories (South
Logan, UT). Blots were washed in Tris-buffered saline 0.1%
Tween-20, incubated with horse-radish-peroxidase (HRP)-conju-
gated goat anti-rabbit IgG (Bio-Rad Laboratories, Hercules, CA)
to reveal phosphorylated proteins or HRP-conjugated goat anti-
mouse IgG (GE Healthcare, Little Chalfont, UK) to reveal control
proteins. The proteins were developed with the enhanced
chemiluminescence ECL reagents from Pierce (Rockford, IL).
Densitometry was performed on scanned immunoblot imaging
using Model GS-700 Imaging Densitomer (Biorad, Laboratories)
and Multi-Analyst software to obtain OD. The relative OD for
each band was calculated by normalizing the OD for the
corresponding b actin OD.
mRNA Cytokine Expression by TaqMan Real-Time RT-PCR
Analysis
To measure cytokine mRNA expression, TaqMan Real-time
RT-PCR analysis was used (Applied biosystems, Foster City, CA).
Total RNA was extracted from infected MDDC at different time
points, and reverse transcription was carried out as previously
described [21,24]. TaqMan assays were performed according to
manufacturer’s instructions with an ABI 7700 thermocycler
(Applied biosystems). Human b actin was analyzed as an internal
control, and mRNA transcript levels were expressed as fold
increase normalized to b actin. Fold changes in gene expression
levels were calculated by comparison with the gene expression in
mock sample, which were assigned an arbitrary value of 1.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
software (San Diego, California, US). For the overall comparison
of median values, a statistical analysis, using Fridman test, was
performed. For post-test pairwise comparisons, Wilcoxon matched
pairs test, adjusting for 6 multiple comparisons (0.05/6 = 0.0083),
was then used. P#0.0083 was considered statistically significant.
Results
Impact of BPZE1 on phenotypic maturation and cytokine
production of RSV-infected MDDC
To determine the conditions of RSV infection, MDDC were
infected for 2 h with RSV at two MOI: 0.5 and 1 plaque forming
units/cell. The infection was monitored by measuring the RSV L
gene transcripts as index of viral copies. MDDC were more
efficiently infected at a MOI of 1 compared to a MOI of 0.5, both
at 24 h and 48 h (0.27E+04 vs 0.08E+04 viral copies/mg RNA,
and 8.00E+04 vs 5.40E+04 viral copies/mg RNA, respectively).
Therefore, the MOI of 1 was chosen for the subsequent
experiments.
In a previous study we found that 2 h of MDDC infection by
BPZE1 at a bacteria/cell ratio of 100:1 followed by 24 h of culture
allowed for optimal MDDC maturation and that, at this ratio,
BPZE1 promoted significant resistance of MDDC to apoptosis,
spontaneously occurring when the cells were not stimulated [16].
To assess whether RSV and BPZE1 co-infections affected cell
viability, necrosis and apoptosis were measured in MDDC infected
with BPZE1, RSV, or both. Mock treated- MDDC were included
as control. We found that whereas RSV, in agreement with
previous studies [25], enhanced the levels of apoptosis with respect
to mock treated-MDDC, protection from spontaneous apoptosis
was observed in double infected MDDC (23.668.7 vs 33.068.3%
of Annexin V positive cells, mean values of 4 experiments
performed at 48 h in BPZE1/RSV- vs RSV- treated MDDC,
respectively. Apoptosis rate of mock treated MDDC in the same
experiments was 17.464.4% of positive cells).
The transition from an immature to a mature stage endows DC
with the capacity to couple innate to adaptive immunity. To
evaluate this transition in our experimental conditions, MDDC
were infected with BPZE1, RSV or both. Mock treated- MDDC
were included as control. The phenotypic maturation of MDDC
BPZE1 Enhances Adaptive Immune Responses to RSV
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was evaluated by monitoring the surface expression of CD80,
CD83 and CD38. CD80 co-stimulatory molecule is involved in
APC functions of MDDC, whereas CD83 is one of the best-known
surface markers for fully mature MDDC [26], and CD38 is an
early maturation marker induced by microbial molecules and
cytokines such as IFNc produced during the innate immune
response [22,27].
RSV infection induced a modest up-regulation of the markers
analyzed, with a significant CD38 increase, as compared to mock
treated cells. When MDDC were treated simultaneously with
BPZE1 and RSV, the induction of a fully mature phenotype was
observed, with higher CD38 expression as compared to BPZE1-
challenged MDDC (Figure 1).
DC maturation leads to the production of several key
inflammatory and immunoregulatory cytokines, which rule the
development of cell-mediated and humoral immune responses
[28]. In order to determine the impact of BPZE1, RSV, or
BPZE1/RSV double infection on the release of cytokines involved
in the polarization of Th responses, we measured IL-10, a cytokine
with a predominant immunosuppressive function, IL-12p70, a
pro-inflammatory cytokine important in Th1 polarization, and IL-
23, involved in Th17 polarization [28], in the supernatants of
infected MDDC. Figure 2 shows that BPZE1 induced the
production of high levels of IL-10, low levels of IL-12p70,
(measurable only in a minority of the samples analyzed) and
appreciable levels of IL-23, as compared to mock-treated MDDC.
RSV-infected MDDC did not induce the production of measur-
able amounts of IL-10 and induced barely detectable levels of IL-
12p70 and IL-23. However, when MDDC were co-infected with
RSV and BPZE1 IL-10 and IL-23 were produced at levels similar
to those induced by BPZE1 alone. Interestingly, IL-12p70
secretion was increased in double infected cultures with respect
to BPZE1-, RSV- infected cells and mock- treated MDDC,
reaching a statistical significance as compared to RSV- and mock-
treated MDDC.
Impact of BPZE1 on RSV-induced allogeneic T cell
proliferation and Th response
A key function of mature DC is antigen presentation to T
lymphocytes and polarization of the immune response [29]. The
antigen-presenting ability was evaluated by measuring the
proliferation of T lymphocytes co-cultured for 6 days with
allogeneic MDDC. As shown in Figure 3, MDDC stimulated
with BPZE1 efficiently induced T cell proliferation. In contrast,
RSV-infected MDDC induced only basal levels of T cell
proliferation, in agreement with previous studies [30,31]. When
BPZE1 and RSV were added simultaneously, MDDC very
efficiently induced allogeneic T cell proliferation, with an
increasing trend as compared to the proliferation induced by
BPZE1-treated MDDC.
We next investigated the capacity of BPZE1-, RSV-, or double-
infected MDDC to polarize the T cell responses. Polarization
experiments were performed by co-culturing purified allogeneic
CD3 T lymphocytes with BPZE1-, RSV- or BPZE1/RSV-
infected MDDC and measuring the levels of three key cytokines
of polarized Th responses: IFNc, landmark of Th1 immune
responses, IL-5 produced by Th2 effectors and IL-17, mediator of
Th17 responses [28]. BPZE1-treated MDDC induced a mixed
Th1/Th17 polarization, with high levels of IFNc and IL-17 but
basal levels of IL-5, as expected from previous observations [16].
RSV-infected MDDC, instead, showed a Th1 polarization, as
evidenced by consistent levels of IFNc and clearly did not induce
IL-17 production. The addition of BPZE1 to RSV-infected
MDDC caused a marked and significant increase of IL-17 and
IFNc, compared to RSV-infected and mock-treated MDDC. At
the same time IL-5 induction was statistically decreased with
respect to RSV and BPZE1- infected MDDC (Figure 4). Overall,
when BPZE1 was added to RSV, the MDDC-mediated polari-
zation shifted towards a clear Th1/Th17 profile.
RSV- and BPZE1-induced signaling pathways and gene
profile in MDDC
To better understand the activation of pro-inflammatory
cytokines in our system, we characterized the pathways triggered
by RSV in infected MDDC and the influence exerted by BPZE1.
We analyzed the phosphorylation of the transcription factor
STAT1, pivotal in the regulation of the MyD88-independent
pathway [32], the phosphorylation of IkBa, a process required for
the activation of NF-kB, and the phosphorylation of p44/p42
(ERK1/2) and p38, MAPKs family members involved in the
MyD88-dependent pathway [33].
Figure 5 shows that BPZE1 treatment induced phosphorylation
of ERK1/2, p38, and IkBa, similar to the results obtained with the
virulent B. pertussis in a previous study [34], but not of STAT1.
Conversely, RSV induced in MDDC phosphorylation of STAT1
at all time points analyzed, but not of the other proteins tested
(except trace amount of phosphorylated p38 at 24 h, in Figure 5
panel A). These results indicate that, in our system, RSV triggers
Figure 1. Impact of BPZE1 on phenotypic maturation of RSV-infected MDDC.MDDC were treated with BPZE1 (bacteria/cell ratio 100:1), RSV
(MOI of 1) or both. After 24 h, cells were analyzed for the indicated surface markers associated with a mature phenotype. Mock-infected cells were
used as control. Fluorescence data are reported as median fluorescence intensity (MedFI) for CD80 and CD38, and as percentage of positive cells for
CD83. Values are expressed as medians with interquartile range of seven independent experiments performed with MDDC obtained from different
donors. Statistical significant differences are indicated by * (P#0.0083).
doi:10.1371/journal.pone.0100166.g001
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mainly a MyD88-independent pathway while BPZE1 a MyD88-
dependent pathway. When MDDC were simultaneously infected
with BPZE1 and RSV the phosphorylation of all proteins tested
was observed. Overall these data indicate that BPZE1 and RSV
trigger two different signaling pathways leading to a strong
activation of MDDC.
The MyD88-dependent pathway is known to be responsible for
the activation of several pro-inflammatory genes, including those
encoding for IL-6 and the p40 subunit of IL-12p70 [35,36]. On
the other hand, the MyD88-independent signaling is responsible
for the activation of intracellular pathways that, through the
activation of IRF3, drive the production of IFNb and, conse-
quently, the expression of IFN-inducible genes such as those
coding for CCL5 (also known as RANTES) and the p35 subunit of
IL-12p70 [36,37], both of which have been shown to play an
important part in the response to RSV infection in mice [18].
To confirm the differential triggering of MyD88-dependent or -
independent pathways by BPZE1 and RSV in MDDC, we
analyzed the expression levels of the above mentioned genes in our
experimental conditions (Figure 6). As expected, BPZE1 was able
to induce the expression of the genes coding for IL-6 and the IL-
12p40 subunit, which were not induced by RSV. In contrast, RSV
triggered the expression of the genes coding for IFNb, CCL5 and
the IL-12p35 subunit, which are ruled by MyD88-independent
signaling and were not (or marginally for CCL5) induced by
BPZE1. When double infections were performed, we observed the
expression of all the genes tested, albeit with a decrease for IFNb
compared to RSV treatment alone. Overall these data confirm
those obtained by Western Blot analysis and indicate the
simultaneous activation of two different pathways in double
infected MDDC.
Discussion
It is known that RSV can infect human DC in vitro and activate
MDDC [25,38–40]. The present study shows that the live
attenuated B. pertussis vaccine candidate BPZE1 can infect human
MDDC and modulate the immune response to RSV by (i)
enhancing their maturation; (ii) enhancing, IL-12p70 production
and (iii) switching their polarization ability to a Th1/Th17
pattern.
Despite to the basal levels of CD80 and CD83 induction, RSV
significantly enhanced surface expression of CD38 on MDDC.
CD38 is an ectoenzyme and a marker of maturation and
activation involved in many MDDC functions, including migra-
tion, survival and the induction of Th1 polarized immune
responses [22,27]. Enhanced CD38 expression is also functionally
involved in IL-12p70 induction [27]. In our study, RSV alone did
not induce release of IL-12p70, but double-infected MDDC
released more IL-12p70 than MDDC primed with BPZE1 alone.
Further studies are needed to evaluate if the up-regulation of
CD38 may be involved in the enhanced release of IL-12p70.
Other cytokines are crucially involved in the orchestration of the
adaptive immune response such as IL-10 and IL-23. We observed
an increase of these cytokines in double-infected cells suggesting a
positive effects of infection with RSV and BPZE1. Mature DC
possess remarkable antigen-presenting abilities and activate the
proliferation of T cells in the lymph nodes. RSV infection of DC
affects the ability to activate the proliferation of T cells [40,41],
possibly because of RSV’s ability to suppress the formation of
Figure 2. Impact of BPZE1 on IL-10, IL-12p70 and IL-23 production of RSV-infected MDDC. MDDC were treated with BPZE1 (bacteria/cell
ratio of 100:1), RSV (MOI of 1) or double infected with BPZE1 and RSV. Mock-infected cells were used as control. After 24 h, cytokines released in the
culture media were measured by ELISA. Values are expressed as medians with interquartile range from 13 (IL-10 and IL-23) and from 15 (IL-12p70)
independent experiments performed with MDDC obtained from different donors and expressed as ng/ml (IL-10) or pg/ml (IL-12p70 and IL-23).
Statistical significant differences are indicated by * (P#0.0083).
doi:10.1371/journal.pone.0100166.g002
Figure 3. Impact of BPZE1 on RSV-induced allogeneic T cell
proliferation. MDDC were infected with RSV (MOI of 1), BPZE1
(bacteria/cell ratio of 100:1), or both. Mock-infected cells were added as
control. After 48 h, MDDC were co-cultured with allogeneic purified T
cells at increasing T cells/MDDC ratios (5/1, 10/1, 20/1, 40/1) for 6 d.
Results are reported as percentages of BrdU positive cells (mean 6 SEM
of 4 independent experiments performed with MDDC obtained from
different donors).
doi:10.1371/journal.pone.0100166.g003
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immunological synapses between RSV-infected DC and T cells (as
demonstrated in murine DC, ref [25]), or the secretion of
regulatory cytokines released by RSV-infected DC, such as IFN-
l and -a, involved in the suppression of T cells [42]. Our study
confirms the inability of RSV-infected MDDC to activate
allogeneic T cell proliferation and, at the same time, evidences
the property of BPZE1 to overcome the inhibition of T cell
responses mediated by RSV.
Our data show a tendency by RSV-primed MDDC to activate a
Th1 response, although the Th2 component was not increased as
Figure 4. Impact of BPZE1 on RSV-induced T lymphocyte polarization. MDDC were treated with BPZE1 (bacteria/cell ratio of 100:1), RSV
(MOI of 1) or both. Mock-infected cells were added as control. After 48 h, treated MDDC were cultured with purified allogeneic CD3 T cells. On day12,
supernatants were collected, and IFN-c (Th1), IL-5 (Th2) and IL-17 (Th17) were measured by ELISA. Values are expressed as medians with interquartile
range of 13 independent experiments performed with MDDC obtained from different donors and expressed as ng/ml (IFNc) or pg/ml (IL-5 and IL-17).
Statistical significant differences are indicated by * (P#0.0083).
doi:10.1371/journal.pone.0100166.g004
Figure 5. RSV- and BPZE1-induced signaling pathways in MDDC. A: Total cell lysates were prepared from MDDC treated with BPZE1 (100:1),
RSV (MOI of 1) or both at the indicated time-points. Mock-infected cells were added as control. Proteins were resolved by 10% SDS-PAGE and Western
blot analysis was performed to detect the phosphorylation of STAT1, IkBa, ERK1/2 and p38. Human phosphorylated b actin was used to normalize the
results. Data are from one representative of three independent experiments performed with MDDC obtained from different donors. B: Histograms
represent means of the relative optical density of phosphorylated proteins from three independent experiments. Error bars represent SEM.
doi:10.1371/journal.pone.0100166.g005
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compared to that induced by mock-primed MDDC. In this
regard, considering the relative high level of IL-5 induced by mock
treated MDDC, our data suggest that this ex vivo system is already
Th2 oriented and that the capacity to induce this polarization
could be inherently driven by immature or low-mature MDDC
[43,44]. BPZE1/RSV co-infected MDDC shifted the Th response
towards a Th1/Th17 profile, with IFNc levels higher than those
induced by RSV-MDDC (P= 0.0049). This shift in Th polariza-
tion is of particular interest considering that the clearance of RSV
infection in healthy individuals needs the activation of IFNc-
secreting CD8 and CD4 T cells, and that the unbalance of Th1
and Th2 response is associated with severe forms of RSV-induced
diseases [45,46].
Animal studies have associated Th2 responses with increased
RSV-induced pulmonary pathology (38, 39). Depletion of the
Th2-associated cytokine IL-4 prior to acute RSV infection has
been reported to decrease lung inflammation and mucus
production [47]. By contrast, Th1 responses may be essential for
promoting protective immunity, and depletion of the Th1
polarizing cytokine IL-12p70 results in increased production of
the Th2-associated cytokine IL-13, along with increased airway
resistance, pulmonary inflammation and mucus production [48].
It is therefore possible that, in infected individuals, BPZE1 could
protect against RSV-mediated detrimental Th2-associated re-
sponses and ensure the generation of putative protective Th1/
Th17 responses. These data are in agreement with recent
evidences in mice where BPZE1 did not exacerbate the
inflammatory response to infection with RSV, but rather provided
considerable protection. This non-specific effect was long-lasting
and depended on the cytokine IL-17 [18].
The role of IL-17 in RSV disease appears to be highly
dependent on context [49]; in mice, IL-17A is reported to inhibit
airway reactivity induced by RSV infection during allergic airway
inflammation [50]. In a human study, an increase of local IL-17
occurs during the recovery of children hospitalized with RSV [51].
RSV is able to activate different receptors of the innate immune
response, including TLRs [52,53] and B. pertussis has been shown
to trigger TLR2 and TLR4 in human cells and mice [24,34,54–
56].
We hypothesized that the effects exerted by BPZE1 on RSV-
infected MDDC could be mediated by the activation of a different
intracellular signaling pathway that may act co-operatively and
foster the production of IL-12p70, antigen-presentation activity,
and the capacity to drive Th1 cell expansion. Our data show that
BPZE1 is able to activate MyD88 signaling in MDDC but does
not activate STAT1 phosphorylation associated with the MyD88-
independent pathway. In contrast, RSV activates STAT1
phosphorylation but not the MyD88-dependent pathway. As a
result, co-infection activates both pathways. This was confirmed
by transcriptional analyses of gene expression induced by both the
MyD88-dependent and -independent pathways. Interestingly, the
expression of both subunit genes of IL-12p70 was induced by
double infections, and a significant increment of IL-12p70 levels
released by MDDC was detected (Figure 2, P = 0.0068 BPZE1+
RSV vs RVS; P = 0.0024 BPZE1+RSV vs Mock).
Overall our results indicate that the live attenuated B. pertussis
vaccine candidate BPZE1 can rescue the RSV-induced immune
response in human MDDC, enhances the maturation state of the
MDDC, increases IL-12p70 production and induces a Th1/Th17
Figure 6. RSV- and BPZE1-induced IL-6, IFNb, CCL5, IL-12p40 and IL-12p35 gene expression in MDDC. MDDC were treated with BPZE1
(100:1), RSV (MOI of 1) or both. Mock-infected cells were added as control. Total RNA was extracted at the indicated time points. Kinetics of mRNA
expression for p40 and p35 subunits of IL-12p70, IL-6, IFNb and CCL5 was evaluated by real-time quantitative RT-PCR. The mRNA transcripts were
normalized with respect to the endogenous reference (human b actin) sample. Data were expressed as fold increase (mean 6 SEM of four
experiments) with respect to mock-treated cells at 5 h.
doi:10.1371/journal.pone.0100166.g006
BPZE1 Enhances Adaptive Immune Responses to RSV
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e100166
cytokine profile. These data were supported by the results of the
intracellular signaling pathway.
The present study gives further support for the use of BPZE1 in
infants and young children not only as a vaccine against pertussis
(http://www.child-innovac.org) [10], but also for possible benefits
during viral infections, in the acceleration of postnatal immune
maturation and in protection against allergic disorders, as it may
play an important role as an adjuvant that can drive a protective
Th1/Th17 response, important in RSV infection and in other
pathological disorders.
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